company background image
ALDX

Aldeyra TherapeuticsNasdaqCM:ALDX Stock Report

Last Price

US$3.49

Market Cap

US$202.7m

7D

-8.4%

1Y

-73.6%

Updated

19 Jan, 2022

Data

Company Financials +
ALDX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ALDX Stock Overview

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Aldeyra Therapeutics
Historical stock prices
Current Share PriceUS$3.49
52 Week HighUS$15.95
52 Week LowUS$3.35
Beta1.52
1 Month Change-50.43%
3 Month Change-57.13%
1 Year Change-73.60%
3 Year Change-58.84%
5 Year Change-38.77%
Change since IPO-51.53%

Recent News & Updates

Dec 23

Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap

Aldeyra Therapeutics reported top-line results from their phase three trial, TRANQUILITY, evaluating Reproxalap in the treatment of dry eye disease; the trial missed the primary endpoint of improving ocular redness. The market reacted sharply, having sent shares down by ~45% as of the time of writing. At the current share price of ~$4.00, the stock trades below its cash value per share. I believe that this is an overreaction, as TRANQUILITY achieved a secondary endpoint deemed valid by the FDA for approval - TRANQUILITY 2 also still needs to read out. On top of this, Aldeyra is well-capitalized for the near future, still has a path to approval for Reproxalap in allergic conjunctivitis, and has several other early-stage clinical assets.

Dec 22
Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?

Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

ALDXUS BiotechsUS Market
7D-8.4%-5.9%-3.5%
1Y-73.6%-18.4%10.2%

Return vs Industry: ALDX underperformed the US Biotechs industry which returned -14.3% over the past year.

Return vs Market: ALDX underperformed the US Market which returned 13.7% over the past year.

Price Volatility

Is ALDX's price volatile compared to industry and market?
ALDX volatility
ALDX Average Weekly Movement16.9%
Biotechs Industry Average Movement10.1%
Market Average Movement6.6%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: ALDX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: ALDX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200411Todd Bradyhttps://www.aldeyra.com

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company’s lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma.

Aldeyra Therapeutics Fundamentals Summary

How do Aldeyra Therapeutics's earnings and revenue compare to its market cap?
ALDX fundamental statistics
Market CapUS$202.74m
Earnings (TTM)-US$53.31m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALDX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$53.31m
Earnings-US$53.31m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.92
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio7.0%

How did ALDX perform over the long term?

See historical performance and comparison

Valuation

Is Aldeyra Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ALDX ($3.49) is trading below our estimate of fair value ($124.37)

Significantly Below Fair Value: ALDX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ALDX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ALDX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALDX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALDX is good value based on its PB Ratio (0.9x) compared to the US Biotechs industry average (2.2x).


Future Growth

How is Aldeyra Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

54.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALDX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALDX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALDX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALDX is forecast to have no revenue next year.

High Growth Revenue: ALDX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALDX is forecast to be unprofitable in 3 years.


Past Performance

How has Aldeyra Therapeutics performed over the past 5 years?

-19.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALDX is currently unprofitable.

Growing Profit Margin: ALDX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALDX is unprofitable, and losses have increased over the past 5 years at a rate of 19.6% per year.

Accelerating Growth: Unable to compare ALDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: ALDX has a negative Return on Equity (-24.27%), as it is currently unprofitable.


Financial Health

How is Aldeyra Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ALDX's short term assets ($246.8M) exceed its short term liabilities ($11.9M).

Long Term Liabilities: ALDX's short term assets ($246.8M) exceed its long term liabilities ($15.6M).


Debt to Equity History and Analysis

Debt Level: ALDX has more cash than its total debt.

Reducing Debt: ALDX's debt to equity ratio has increased from 5.1% to 7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALDX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ALDX has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 23% each year.


Dividend

What is Aldeyra Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALDX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALDX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Todd Brady (49 yo)

10yrs

Tenure

US$2,421,362

Compensation

Dr. Todd C. Brady, M.D., Ph D., is a Director at F-star Therapeutics, Inc since November 20, 2020. He has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. since January 2012.Dr...


CEO Compensation Analysis

Compensation vs Market: Todd's total compensation ($USD2.42M) is above average for companies of similar size in the US market ($USD1.10M).

Compensation vs Earnings: Todd's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ALDX's management team is considered experienced (2.1 years average tenure).


Board Members

Experienced Board: ALDX's board of directors are considered experienced (8.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.2%.


Top Shareholders

Company Information

Aldeyra Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Aldeyra Therapeutics, Inc.
  • Ticker: ALDX
  • Exchange: NasdaqCM
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$202.741m
  • Shares outstanding: 58.09m
  • Website: https://www.aldeyra.com

Number of Employees


Location

  • Aldeyra Therapeutics, Inc.
  • 131 Hartwell Avenue
  • Suite 320
  • Lexington
  • Massachusetts
  • 2421
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 00:06
End of Day Share Price2022/01/18 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.